On November 6, 2023, Celest Therapeutics, a China-based biotechnology company focused on developing intelligent CAR-immune cell therapy for treatment of challenging solid tumors, and Senti Biosciences announced a new strategic collaboration for the clinical development of SENTI-301A to treat solid tumors in China. Celest will lead clinical development, operations, and manufacturing for the advancement of SENTI-301A and Senti Biosciences will be eligible to receive up to $156 million in certain milestone payments, in addition to potential tiered royalty payments.

Wilson Sonsini Goodrich & Rosati represented Celest Therapeutics in the transaction. The Wilson Sonsini team includes Chi-Fei Wang and Tony Nguyen from the firm’s technology transactions group and Jie Zhu and Xuchao Dong from the Greater China corporate group.

For more information, please see the press release.